Curcumin/Doxorubicin

姜黄素/多柔比星

Report date: 2022/09/19 14:16:46

Base Information

Drug NameCurcumin/Doxorubicin
Drug Alias Namepolyphenol-curcuminoid/PEG-PE doxorubicin complexImx-110
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Anthracycline antibiotics
Mechanisms of ActionTopoisomerase II inhibitorsDNA intercalators
TargetsTopoisomerase IIDNA
Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsPancreatic Neoplasms +[4
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaBrazil
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmix Biopharma
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsSolid tumoursOvarian NeoplasmsPancreatic Neoplasms +[4
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A